2010
Clostridium perfringens enterotoxin carboxy-terminal fragment is a novel tumor-homing peptide for human ovarian cancer
Cocco E, Casagrande F, Bellone S, Richter CE, Bellone M, Todeschini P, Holmberg JC, Fu HH, Montagna MK, Mor G, Schwartz PE, Arin-Silasi D, Azoudi M, Rutherford TJ, Abu-Khalaf M, Pecorelli S, Santin AD. Clostridium perfringens enterotoxin carboxy-terminal fragment is a novel tumor-homing peptide for human ovarian cancer. BMC Cancer 2010, 10: 349. PMID: 20598131, PMCID: PMC2908101, DOI: 10.1186/1471-2407-10-349.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAdenocarcinoma, Clear CellAnimalsCarcinoma, PapillaryCarcinoma, Squamous CellChlorocebus aethiopsClaudin-3Claudin-4Clostridium perfringensCystadenocarcinoma, SerousDrug Resistance, NeoplasmEnterotoxinsFemaleFibroblastsFlow CytometryHumansMembrane ProteinsMiceMice, SCIDOvarian NeoplasmsPeptide FragmentsReverse Transcriptase Polymerase Chain ReactionRNA, MessengerSpheroids, CellularTissue DistributionTransplantation, HeterologousTumor Cells, CulturedUterine Cervical NeoplasmsVero CellsConceptsChemotherapy-resistant ovarian cancerClostridium perfringens enterotoxinOvarian cancerOvarian carcinoma cell linesClaudin-3Carcinoma cell linesNovel tumor-homing peptideCarboxy-terminal fragmentTumor cellsResistant ovarian cancer cell linesCell linesNew diagnostic tracersCPE peptideOvarian cancer cell linesResistant ovarian cancer cellsResistant ovarian carcinomaHuman ovarian cancerRelevant animal modelsOvarian tumor cellsOvarian cancer cellsChemotherapy-resistant ovarian cancer cellsHuman epithelial tumorsTime-dependent internalizationCancer cell linesBio-distribution studies
2009
Development and characterization of a human single-chain antibody fragment against claudin-3: a novel therapeutic target in ovarian and uterine carcinomas
Romani C, Comper F, Bandiera E, Ravaggi A, Bignotti E, Tassi RA, Pecorelli S, Santin AD. Development and characterization of a human single-chain antibody fragment against claudin-3: a novel therapeutic target in ovarian and uterine carcinomas. American Journal Of Obstetrics And Gynecology 2009, 201: 70.e1-70.e9. PMID: 19426958, PMCID: PMC3701950, DOI: 10.1016/j.ajog.2009.02.010.Peer-Reviewed Original ResearchMeSH KeywordsCarcinoma, PapillaryCell Line, TumorCell SeparationClaudin-3Enzyme-Linked Immunosorbent AssayFemaleFlow CytometryGene LibraryHumansImmunoglobulin FragmentsMembrane ProteinsMicroscopy, ConfocalOvarian NeoplasmsSelf-Sustained Sequence ReplicationSensitivity and SpecificitySurface Plasmon ResonanceUterine Cervical NeoplasmsConceptsClaudin-3Uterine serous carcinoma cell linesSerous papillary carcinomaHuman antibody phage display libraryNovel therapeutic targetEnzyme-linked immunosorbent assayEnzyme-linked immunosorbentHuman single-chain antibody fragmentAntibody phage display libraryCarcinoma cell linesUterine carcinomaNovel antitumor agentsPapillary carcinomaTherapeutic targetSingle-chain antibody fragmentHuman antibodiesHuman malignanciesImmunosorbent assayConformational epitopesPhage display libraryCarcinomaCell linesSurface immunofluorescenceCell surface immunofluorescenceAntitumor agents
2008
Claudin‐7 expression in human epithelial ovarian cancer
TASSI RA, BIGNOTTI E, FALCHETTI M, RAVANINI M, CALZA S, RAVAGGI A, BANDIERA E, FACCHETTI F, PECORELLI S, SANTIN AD. Claudin‐7 expression in human epithelial ovarian cancer. International Journal Of Gynecological Cancer 2008, 18: 1262-1271. PMID: 18298564, DOI: 10.1111/j.1525-1438.2008.01194.x.Peer-Reviewed Original ResearchConceptsEpithelial ovarian carcinomaHistologic typeClaudin-7 expressionClaudin-7Ovarian carcinomaOvarian cancerPeritoneal cavityEOC cellsMetastatic epithelial ovarian carcinomaHuman epithelial ovarian cancerCLDN-7 expressionMain histologic typesEpithelial ovarian cancerProtein levelsGrade of differentiationReverse transcription-polymerase chain reactionTranscription-polymerase chain reactionTight junction proteinsNovel diagnostic markerEpithelium cell lineSingle neoplastic cellsHuman normal tissuesPleural effusionPathologic stageInflammatory cells
2007
Claudin 4 identifies a wide spectrum of epithelial neoplasms and represents a very useful marker for carcinoma versus mesothelioma diagnosis in pleural and peritoneal biopsies and effusions
Facchetti F, Lonardi S, Gentili F, Bercich L, Falchetti M, Tardanico R, Baronchelli C, Lucini L, Santin A, Murer B. Claudin 4 identifies a wide spectrum of epithelial neoplasms and represents a very useful marker for carcinoma versus mesothelioma diagnosis in pleural and peritoneal biopsies and effusions. Virchows Archiv 2007, 451: 669-680. PMID: 17609977, DOI: 10.1007/s00428-007-0448-x.Peer-Reviewed Original ResearchConceptsDiagnosis of mesotheliomaSpindle cell neoplasmCell neoplasmsEpithelial neoplasmsFollicular dendritic cell sarcomaDendritic cell sarcomaBiphasic synovial sarcomaNeoplastic mesothelial cellsMetastatic tumor cellsSerosal metastasisPeritoneal biopsiesReactive effusionsMetastatic carcinomaSynovial sarcomaPrimary carcinomaCell sarcomaMesotheliomaMesothelial cellsMesothelioma diagnosisReactive mesotheliumUseful markerCarcinomaClaudin-4NeoplasmsCytological samplesOverexpression of Clostridium perfringens Enterotoxin Receptors Claudin-3 and Claudin-4 in Uterine Carcinosarcomas
Santin AD, Bellone S, Siegel ER, McKenney JK, Thomas M, Roman JJ, Burnett A, Tognon G, Bandiera E, Pecorelli S. Overexpression of Clostridium perfringens Enterotoxin Receptors Claudin-3 and Claudin-4 in Uterine Carcinosarcomas. Clinical Cancer Research 2007, 13: 3339-3346. PMID: 17545541, DOI: 10.1158/1078-0432.ccr-06-3037.Peer-Reviewed Original ResearchConceptsCarcinosarcoma cell lineClaudin-3Claudin-4Uterine carcinosarcomaClaudin-4 protein expressionCell linesClaudin-4 receptorsCytotoxic Clostridium perfringensNormal endometrial cellsTumor cell necrosisType-specific therapiesImmunodeficient mouse xenograftsAggressive uterine tumorsHigh-affinity receptorQuantitative reverse transcription PCREndometrial cancerAggressive variantUterine tumorsTumor disappearancePrimary tumorReverse transcription-PCREndometrial cellsNovel therapiesReceptor expressionTherapeutic effectOverexpression of claudin‐3 and claudin‐4 receptors in uterine serous papillary carcinoma
Santin AD, Bellone S, Marizzoni M, Palmieri M, Siegel ER, McKenney JK, Hennings L, Comper F, Bandiera E, Pecorelli S. Overexpression of claudin‐3 and claudin‐4 receptors in uterine serous papillary carcinoma. Cancer 2007, 109: 1312-1322. PMID: 17326053, DOI: 10.1002/cncr.22536.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAnimalsClaudin-3Claudin-4Clostridium perfringensCystadenocarcinoma, PapillaryCystadenocarcinoma, SerousDrug Resistance, NeoplasmEnterotoxinsFemaleGene ExpressionHumansInjections, IntraperitonealMembrane ProteinsMiceMice, SCIDMiddle AgedReverse Transcriptase Polymerase Chain ReactionRNA, MessengerTumor Cells, CulturedUp-RegulationUterine Cervical NeoplasmsXenograft Model Antitumor AssaysConceptsUterine serous papillary carcinomaClaudin-4 receptorsUSPC cell linesSerous papillary carcinomaClaudin-3Endometrial cancerPapillary carcinomaClaudin-4 protein expressionChemotherapy-resistant variantsCytotoxic Clostridium perfringensSublethal intraperitoneal injectionsReverse transcriptase-polymerase chain reactionQuantitative reverse transcriptase-polymerase chain reactionTumor cell necrosisSCID mouse xenograftsType-specific therapiesDose-dependent cytotoxic effectCell linesTight junction proteinsControl tissue samplesHigh-affinity receptorAggressive variantTumor disappearanceIntraperitoneal injectionPolymerase chain reaction
2006
Differential gene expression profiles between tumor biopsies and short-term primary cultures of ovarian serous carcinomas: Identification of novel molecular biomarkers for early diagnosis and therapy
Bignotti E, Tassi RA, Calza S, Ravaggi A, Romani C, Rossi E, Falchetti M, Odicino FE, Pecorelli S, Santin AD. Differential gene expression profiles between tumor biopsies and short-term primary cultures of ovarian serous carcinomas: Identification of novel molecular biomarkers for early diagnosis and therapy. Gynecologic Oncology 2006, 103: 405-416. PMID: 16725184, DOI: 10.1016/j.ygyno.2006.03.056.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overBiomarkers, TumorBiopsyClaudin-3Claudin-4Cystadenocarcinoma, SerousEpithelial CellsFemaleGene Expression ProfilingHumansImmunohistochemistryKallikreinsMammaglobin AMembrane ProteinsMiddle AgedNeoplasm ProteinsOvarian NeoplasmsReverse Transcriptase Polymerase Chain ReactionTumor Cells, CulturedUteroglobinConceptsGene expression profilesGene expression profilingExpression profilingExpression profilesGenetic fingerprintsDifferential gene expression profilesNovel molecular biomarkersGene expression productsOvarian serous papillary carcinomaGene expression dataHuman genesGene expressionMolecular biomarkersOligonucleotide microarraysExpression productsPrimary tumor cell culturesExpression dataQuantitative RT-PCREnterotoxin receptorGenesMicroarray dataKallikrein 6Ovarian serous carcinomaProtein levelsMammaglobin 2
2005
Treatment of Chemotherapy-Resistant Human Ovarian Cancer Xenografts in C.B-17/SCID Mice by Intraperitoneal Administration of Clostridium perfringens Enterotoxin
Santin AD, Cané S, Bellone S, Palmieri M, Siegel ER, Thomas M, Roman JJ, Burnett A, Cannon MJ, Pecorelli S. Treatment of Chemotherapy-Resistant Human Ovarian Cancer Xenografts in C.B-17/SCID Mice by Intraperitoneal Administration of Clostridium perfringens Enterotoxin. Cancer Research 2005, 65: 4334-4342. PMID: 15899825, DOI: 10.1158/0008-5472.can-04-3472.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAnimalsCarcinoma, PapillaryCell Line, TumorClaudin-3Claudin-4Cystadenocarcinoma, SerousDrug Resistance, NeoplasmEnterotoxinsFemaleHumansInjections, IntraperitonealMembrane ProteinsMiceMice, SCIDMiddle AgedOvarian NeoplasmsReceptors, Cell SurfaceUterine Cervical NeoplasmsXenograft Model Antitumor AssaysConceptsClaudin-4 genesRecurrent ovarian cancerPrimary ovarian tumorsOvarian cancerHuman ovarian cancerOvarian tumorsClaudin-3C.B-17/SCID micePrimary human ovarian cancersHuman ovarian cancer xenograftsCytotoxic Clostridium perfringensOvarian tumor burdenAdvanced stage diseaseChemotherapy-resistant diseaseLethal gynecologic malignancyOvarian cancer xenograftsRecurrent ovarian tumorsRelevant clinical modelInhibited tumor growthSCID mouse xenograftsDose-dependent cytotoxic effectTight junction proteinsHigh-affinity receptorQuantitative reverse transcription PCRClostridium perfringens enterotoxinGene expression fingerprint of uterine serous papillary carcinoma: identification of novel molecular markers for uterine serous cancer diagnosis and therapy
Santin AD, Zhan F, Cane' S, Bellone S, Palmieri M, Thomas M, Burnett A, Roman JJ, Cannon MJ, Shaughnessy J, Pecorelli S. Gene expression fingerprint of uterine serous papillary carcinoma: identification of novel molecular markers for uterine serous cancer diagnosis and therapy. British Journal Of Cancer 2005, 92: 1561-1573. PMID: 15785748, PMCID: PMC2362016, DOI: 10.1038/sj.bjc.6602480.Peer-Reviewed Original ResearchConceptsUterine serous papillary cancerNormal endometrial cellsEndometrial cancerAggressive variantClaudin-4Normal endometrial epithelial cellsUterine serous papillary carcinomaAdhesion moleculesNovel therapeutic markerCommon gynecologic tumorsSerous papillary carcinomaParaffin-embedded specimensEndometrial epithelial cellsL1 cell adhesion moleculeType-specific therapiesRas homolog gene familyQuantitative RT-PCRScalar dosesGynecologic tumorsPapillary cancerEndometrial cellsInterleukin-6Cell adhesion moleculeNovel molecular markersPapillary carcinoma
2003
Induction of tumor-specific cytotoxicity in tumor infiltrating lymphocytes by HPV16 and HPV18 E7-pulsed autologous dendritic cells in patients with cancer of the uterine cervix
Santin AD, Bellone S, Palmieri M, Bossini B, Roman JJ, Cannon MJ, Bignotti E, Canè S, Pecorelli S. Induction of tumor-specific cytotoxicity in tumor infiltrating lymphocytes by HPV16 and HPV18 E7-pulsed autologous dendritic cells in patients with cancer of the uterine cervix. Gynecologic Oncology 2003, 89: 271-280. PMID: 12713991, DOI: 10.1016/s0090-8258(03)00083-0.Peer-Reviewed Original ResearchMeSH KeywordsAdultCytotoxicity, ImmunologicDendritic CellsDNA-Binding ProteinsFemaleFlow CytometryHumansImmunotherapy, AdoptiveInterferon-gammaInterleukin-4LeukocytesLymphocytes, Tumor-InfiltratingMembrane ProteinsOncogene Proteins, ViralPapillomavirus E7 ProteinsReceptors, Antigen, T-CellT-Lymphocytes, CytotoxicUterine Cervical NeoplasmsConceptsAutologous dendritic cellsAutologous tumor cellsCervical cancer patientsDendritic cellsPeripheral bloodT cellsTumor-specific cytotoxicityCancer patientsAutologous Epstein-Barr virus-transformed lymphoblastoid cell linesAutologous tumor target cellsType 1 cytokine biasAnti-HLA class ICytotoxic T lymphocyte responsesIFN-gamma-positive cellsTwo-color flow cytometric analysisVirus-transformed lymphoblastoid cell linesEpstein-Barr virus-transformed lymphoblastoid cell linesTumor cellsAdoptive T-cell immunotherapyHPV18 E7 oncoproteinTumor-specific CTLsIntracellular cytokine expressionStandard treatment modalityT lymphocyte responsesT cell populations
2002
Novel immunotherapeutic strategies in gynecologic oncology. Dendritic cell-based immunotherapy for ovarian cancer.
Santin AD, Bellone S, Underwood LJ, O'Brien TJ, Ravaggi A, Pecorelli S, Cannon MJ. Novel immunotherapeutic strategies in gynecologic oncology. Dendritic cell-based immunotherapy for ovarian cancer. Minerva Obstetrics And Gynecology 2002, 54: 133-44. PMID: 12032451.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntigens, NeoplasmCancer VaccinesChildClinical Trials as TopicCombined Modality TherapyDendritic CellsFemaleGPI-Linked ProteinsHumansImmunohistochemistryImmunotherapyKallikreinsMatrix Metalloproteinase 7Membrane ProteinsNeoplasm MetastasisOvarian NeoplasmsSerine EndopeptidasesT-Lymphocytes, CytotoxicTumor Cells, CulturedConceptsTumor antigensOvarian cancerChemotherapy-resistant ovarian cancerOvarian tumor-associated antigensDendritic cell-based immunotherapyTumor-specific immune responsesEffective tumor antigensTherapeutic DC vaccinationNovel immunotherapeutic strategiesStandard treatment modalityCell-based immunotherapyOvarian tumor antigenSpecific immune responseTumor-associated antigensPotential of DCDC vaccinationImmunotherapeutic strategiesDendritic cellsCancer vaccinationCancer patientsGynecologic oncologyTreatment modalitiesNatural adjuvantImmune responseAntigen preparations